Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IZAFE-B.STthis companyiZafe Group AB	SEK 0.20	-9.7×	13.84×	26.99×	-11.74×	-1717.7%	-259.7%	-307.0%	-278.4%	-142.7%	-68.4%	-9.4%	0×	0.12×	-2,627.14×	0.72×	0.0%	2	-4.13	1	C-
ANNX.STAnnexin Pharmaceuticals AB	SEK 9.44	-3.55×	5.25×	0×	-2.81×	-42.7%	0.0%	0.0%	0.0%	-148.0%	-145.6%	-28.3%	0×	0.74×	0×	5.47×	0.0%	1	-32.9	1	C-
BIOWKS.STBio-Works Technologies AB (publ)	SEK 3.17	-15.41×	4.64×	3.66×	-11.76×	-1411.9%	76.5%	-28.0%	-24.4%	-31.0%	-31.6%	-8.4%	0×	2.12×	-90.77×	3.2×	0.0%	4	16.39	2	C
CLS-B.STClinical Laserthermia Systems AB (publ)	SEK 1.74	-4.27×	2.55×	10.18×	-5.92×	-9742.7%	-165.8%	-165.8%	-238.0%	-59.7%	-43.6%	-20.2%	0×	0.82×	-308.57×	3.91×	0.0%	1	-0.88	1	C-
ERMA.STEnorama Pharma AB (publ)	SEK 0.76	-1.77×	-5.66×	48.45×	-2.1×	-104.0%	-2255.6%	-2268.0%	-2743.3%	320.4%	264.9%	-44.7%	0×	0.05×	-4.91×	0.25×	0.0%	2	-29.47	2	C
ININIT.STInitiator Pharma A/S	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Peer median	—	-3.91×	3.6×	6.92×	-4.37×	-758.0%	-82.9%	-96.9%	-131.2%	-45.4%	-37.6%	-24.3%	0×	0.78×	-47.84×	3.56×	0.0%	2	-15.18	2	—